Quick Answer
InMed Pharmaceuticals Inc. reported R&D Expense of $2.85 million for fiscal year 2025.
InMed Pharmaceuticals Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.85M | -11.3% |
| 2024 | $3.22M | -13.8% |
| 2023 | $3.73M | -48.8% |
| 2022 | $7.28M | +36.4% |
| 2021 | $5.34M | -8.1% |
| 2020 | $5.81M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $630.6K | -29.6% | +8.4% |
| September 30, 2025 | $581.6K | -16.9% | -36.1% |
| March 31, 2025 | $909.7K | +38.5% | +1.6% |
| December 31, 2024 | $895.2K | +46.8% | +27.9% |
| September 30, 2024 | $700.1K | -45.8% | +6.6% |
| March 31, 2024 | $656.8K | -25.2% | +7.7% |
| December 31, 2023 | $609.8K | -28.4% | -52.8% |
| September 30, 2023 | $1.29M | -6.3% | +47.1% |
- InMed Pharmaceuticals Inc. showed a decrease of -11.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, InMed Pharmaceuticals Inc.’s r&d expense has declined by 50.9% (from $5.81 million to $2.85 million).
- The most recent figure is from InMed Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: